Loading...
Loading...
Analysts at JMP Securities downgraded
Achillion Pharmaceuticals, Inc.ACHN from Market Outperform to Market Perform and removed the price target of $24.00.
Achillion Pharmaceuticals shares have gained 292.65 percent over the past 52 weeks, while the S&P 500 index has surged 12.70 percent in the same period.
Achillion Pharmaceuticals' shares fell 8.71 percent to9.75 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in